1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and pros- tate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027-35.
2. Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schroder FH, et al. Prostate- specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2014;65(2):329-36.
3. Bokhorst LP, Zhu X, Bul M, Bangma CH, Schroder FH, Roobol MJ. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*. BJU Int. 2012;110(11):1654-60.
4. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdi- agnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-83.
5. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating character- istics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294(1):66-70.
6. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of sys- tematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175(5):1605-12.
7. Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, et al. Cost- effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst. 2015;107(1):366.
8. Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, Auvinen A, Kwiatkowski M, et al. Estimating the harms and benefits of prostate cancer screening as used in common prac- tice versus recommended good practice: A microsimulation screening analysis. Cancer. 2016;122(21):3386-93.
9. Alibhai SM, Krahn MD, Fleshner NE, Cohen MM, Tomlinson GA, Naglie G. The association be- tween patient age and prostate cancer stage and grade at diagnosis. BJU Int. 2004;94(3):303- 6.
10. Cremers RG, Karim-Kos HE, Houterman S, Verhoeven RH, Schroder FH, van der Kwast TH, et al. Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989-2006. Eur J Cancer. 2010;46(11):2077-87.
11. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012;118(12):3062- 70.
12. Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH, et al. A risk- based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79-85.
64
13. Roobol MJ, Schroder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, et al. Importance of pros- tate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol. 2012;30(2):149- 55.
14. van Vugt HA, Roobol MJ, Kranse R, Maattanen L, Finne P, Hugosson J, et al. Prediction of prostate cancer in unscreened men: external validation of a risk calculator. Eur J Cancer. 2011;47(6):903-9.
15. van Vugt HA, Kranse R, Steyerberg EW, van der Poel HG, Busstra M, Kil P, et al. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur J Cancer. 2012;48(12):1809-15.
16. van Vugt HA, Roobol MJ, Busstra M, Kil P, Oomens EH, de Jong IJ, et al. Compliance with biopsy recommendations of a prostate cancer risk calculator. BJU Int. 2012;109(10):1480-8.
17. Trottier G, Roobol MJ, Lawrentschuk N, Bostrom PJ, Fernandes KA, Finelli A, et al. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Random- ized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int. 2011;108(8 Pt 2):E237-44.
18. Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic reso- nance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2015;68(3):438-50.
19. Wegelin O, van Melick HH, Hooft L, Bosch JL, Reitsma HB, Barentsz JO, et al. Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A System- atic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique? Eur Urol. 2016.
20. Roobol MJ, Kirkels WJ, Schroder FH. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int. 2003;92 Suppl 2:48-54.
21. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69(1):16-40.
22. Alberts AR, Schoots IG, Bokhorst LP, van Leenders GJ, Bangma CH, Roobol MJ. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans. Eur Urol. 2016;69(6):1129-34.
23. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 Interna- tional Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40(2):244-52.
24. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190(2):419-26.
25. Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011;29(13):1736-43.
65